{"DataElement":{"publicId":"2677896","version":"1","preferredName":"Tamoxifen Agent Post Clinical Study Enrollment Administered Most Recent Date","preferredDefinition":"the most recent date tamoxifen, an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM), following registration or enrollment on a clinical trial, a type of research study that tests how well new medical treatments or other interventions work in people, was administered.","longName":"TAM_AG_CL_EN_PE_M_DT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2677776","version":"1","preferredName":"Tamoxifen Agent Post Clinical Study Enrollment Administered","preferredDefinition":"information related to the administration of tamoxifen, an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM), following registration or enrollment on a clinical trial, a type of research study that tests how well new medical treatments or other interventions work in people.","longName":"TAM_AGT_P_CL_EN_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2677773","version":"1","preferredName":"Tamoxifen Agent","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04):An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C855:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3969B3BB-0FDB-502B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-05","modifiedBy":"ONEDATA","dateModified":"2007-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2677774","version":"1","preferredName":"Post Clinical Study Enrollment Administered","preferredDefinition":"Post; occuring after.:Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :Enrollment; to insert, register, or enter in a list, catalog, or roll. (Merriam-Webster Online):Given.","longName":"C38008:C15206:C37948:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Enrollment","conceptCode":"C37948","definition":"The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3969B3BB-0FEE-502B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-05","modifiedBy":"ONEDATA","dateModified":"2007-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3969B3BB-0FFF-502B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188928","version":"1","preferredName":"Most Recent Date","preferredDefinition":"the most recent date of an event, assessment, or treatment.","longName":"MOSTRECENT_DT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"mm/dd/yyyy","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208021","version":"1","preferredName":"Most Recent Date","preferredDefinition":"Nearest to the present time.:a particular day specified as the time something has, or will, happen.","longName":"C25577:C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Most Recent","conceptCode":"C25577","definition":"Nearest to the present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-393A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5C89ED4-9CCE-1F2D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-06","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Date of Most Recent Treatment","type":"Preferred Question Text","description":"Date of Most Recent Treatment","url":null,"context":"CTEP"}],"origin":"NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"39791B2E-1AF1-668A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-06","modifiedBy":"CAMPBELB","dateModified":"2008-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}